Bottom line
IXJ vs JDOC: the short answer
IXJ (iShares Global Healthcare ETF) and JDOC (JPMorgan Healthcare Leaders ETF) share a meaningful slice of their top holdings — about 68% by weight.
But IXJ is far broader, holding 124 positions to 61 for JDOC, so beyond the top names it adds exposure JDOC doesn't have.
IXJ is cheaper at 0.38% vs 0.65% — a difference of $27 a year per $10,000 invested.
Over one year, JDOC returned +14.9% vs +14.9% for IXJ.
Updated Nov 19, 2026
IXJ vs JDOC side by side
| IXJ | JDOC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | J.P. Morgan |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.38% | 0.65% |
| Annual cost per $10k | $38 | $65 |
| 10-yr cost on $10k (prospectus) | $480 | $810 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +14.9% | +14.9% |
| 5-yr return (annualized) | +6.4% | — |
| 10-yr return (annualized) | +8.2% | — |
| Best quarter | +13.6% | +11.3% |
| Worst quarter | −11.8% | −11.9% |
| Net assets (fund) | $3.8B | $9.1M |
| Number of holdings | 124 | 61 |
| Portfolio turnover | 2% | 92% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IXJ | JDOC | Difference |
|---|---|---|---|
| 2025 | +14.9% | +14.9% | −0.1% |
| 2024 | +0.6% | −0.6% | +1.2% |
Source: Fund prospectus bar charts
Holdings overlap
17 of IXJ's top 25 holdings also appear in JDOC's top 25.
| Holding | IXJ | JDOC |
|---|---|---|
| Eli Lilly And Company | 10.93% | 7.76% |
| Johnson & Johnson | 7.04% | 4.82% |
| Abbvie Inc. | 5.12% | 7.85% |
| Unitedhealth Group Incorporated | 4.40% | 5.85% |
| Merck & Co., Inc. | 4.12% | 4.82% |
| Astrazeneca Plc | 3.76% | 3.76% |
| Roche Holding AG | 3.75% | 2.82% |
| Novartis AG | 3.71% | 1.60% |
| Thermo Fisher Scientific Incorporated | 2.42% | 3.73% |
| Abbott Laboratories | 2.05% | 3.11% |
| Novo Nordisk A/s | 1.99% | 2.61% |
| Intuitive Surgical, Inc. | 1.83% | 1.93% |
| Cvs Health Corporation | 1.71% | 2.83% |
| Danaher Corporation | 1.56% | 2.16% |
| Bristol-myers Squibb Company | 1.53% | 3.57% |
Source: SEC Form N-PORT
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
FAQ
What is the difference between IXJ and JDOC?
Which is cheaper, IXJ or JDOC?
Should I own both IXJ and JDOC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.